Background
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. At present, the global burden of cardiovascular disease has shifted toward low- and middle-income countries (including China), wherein over 80% of global cardiovascular deaths occur [
1,
2]. Revascularisation and antithrombotic strategies have achieved great success in reducing mortality from acute coronary syndromes (ACS), but the results remain unsatisfactory, especially amongst diabetic patients [
3‐
7].
Fibrinogen (FIB) is an important part of the coagulation pathway and combines with receptors on the platelet membrane to form acute coronary thrombosis [
8,
9]. As an acute phase reactant of inflammation, FIB is associated with long-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) [
10,
11]. Previous studies show that FIB levels are higher in patients with diabetic mellitus (DM) than in controls, which may contribute to the higher thrombotic status of patients with the disease relative to those without [
12,
13]. Amongst patients with acute myocardial infarction (AMI), admission haemoglobin A1c (HbA1c) is an important predictor of the severity of coronary artery stenosis in non-DM and DM patients [
14]. However, few reports have investigated the relationship between baseline FIB levels, glucose metabolism (HbA1c and fasting blood glucose [FBG]) and MACEs in the ACS population after PCI with or without DM; of the studies available, very few originate in China.
The present study was performed to determine the relationship between baseline FIB levels and HbA1c or FBG and explore the role of baseline FIB levels with 2-year MACEs following PCI in ACS patients with or without DM in China.
Discussions
In the current study, we noted that FIB levels were higher in Chinese ACS patients with DM than in non-DM patients after PCI. Baseline plasma FIB was related to HbA1c and FBG, and Cox regression analysis demonstrated that elevated baseline FIB levels are an important and independent predictor of MACEs in the whole and DM patient populations with ACS after PCI but not in non-DM patients over a median of 27.55 months of follow-up. Moreover, landmark survival analysis indicated that, over the first 30 months, patients with elevated FIB showed a large number of MACEs. From the 31st month to the end of follow-up, no significant association was found between FIB level and MACEs; this finding suggests that the relationship between FIB and MACEs is more reliable over short follow-up times than over longer periods. To the best of our knowledge, this study is first to investigate the relationship between FIB, glucose metabolism (HbA1c and FBG) and 2-year MACEs in ACS patients undergoing PCI with or without DM in China.
Fibrinogen is converted into insoluble fibrin by thrombin and expose polymerisation sites facilitating clot formation during activation of the coagulation cascade [
18,
19]. Individuals suffering from diabetes exhibit higher levels of plasma FIB than those without type-2 diabetes mellitus (T
2DM) [
20,
21]. Inflammation is a common antecedent of atherosclerosis and diabetes, and FIB plays essential roles in inflammation and tissue repair [
22,
23]. FIB is related to insulin sensitivity and insulin resistance causes oxidative stress via thrombin formation and the following FIB synthesis, which promotes diabetes complications and adverse clinical consequences [
24‐
28]. However, whether HbA1c and FBG levels are correlated with FIB in patients with ACS, DM-ACS and non-DM-ACS undergoing PCI remains unclear. HbA1c, which reflects the 3-month average plasma glucose concentration, is a marker of long-term glucose management, and HbA1c levels are associated with the prognosis of AMI [
29,
30]. In the present study, the mean FIB level of DM patients was higher than that of non-DM patients. In addition, linear regression analysis showed that admission HbA1c and FBG were positively correlated with FIB in patients with ACS and DM-ACS but not in patients without DM. Our study not only confirms the relationship between FIB and diabetes but also further assesses the relationship between FIB and glucose metabolism indicators in ACS patients with or without DM. However, conflicting results were found. The prospective Multi-Ethnic Study of Atherosclerosis showed that, after adjustment, FIB levels are no longer related to the onset of diabetes in the entire sample [
31]. Similarly, the multicentre epidemiological Insulin Resistance Atherosclerosis Study showed that changes in FIB are not substantially related to incident diabetes [
32]. Obviously, the target population of these two studies are participants without CAD or DM, and their aim is to explore the association between FIB and incident diabetes; these details are very different from those of the current study.
Patients with DM often have accelerated atherosclerosis and more serious clinical outcomes than those without the disease [
33]. A nationwide study from Korea that used data from four consecutive nationwide databases revealed that the absolute burden of CAD remains high as the number of people with diabetes continues to increase [
34]. Previous studies have reported relations between elevated FIB levels and adverse cardiovascular events in CAD and DM patients [
10,
11,
35‐
38]. FIB is regarded as a risk factor in prognostic models for patients with T
2DM, but few studies have explored these relations in patients with DM-ACS, non-DM ACS and whole who underwent PCI [
39]. The major outcome of this study shows that FIB level is an important and independent predictor of 2-year MACEs in patients in the whole ACS and ACS combined with DM populations. By contrast, in non-DM patients, FIB level reflected no relationship with MACEs. As described above, FIB is positively correlated with HbA1c and FBG. In addition, elevated baseline FIB may potentiate MACE through platelet crosslinking, clot formation and arterial thrombosis [
35]. These findings may explain why FIB exhibits no predictive value for MACEs in ACS patients without DM in this study. In the ADVANCE study, a case-cohort study including 3865 patients with T
2DM and baseline CAD or risk factors, IL-6 levels, but not CRP or FIB levels, were significant to the prediction of macro-vascular events and mortality [
40]. CAD is a clinical syndrome with high heterogeneity and different disease severities and prognoses. Different types of CAD may lead to differences in the research results and differences in time during which the studies were conducted may also contribute to the inconsistent results.
Many clinical studies have shown that the risks of target lesion failure, safety and efficacy outcomes amongst patients undergoing PCI are similar after implantation of third-generation drug eluting stents with biodegradable polymers or second-generation drug eluting stents with durable polymers [
41‐
43]. In addition, patients with and without DM show different performance in terms of safety and effectiveness for the same kind of stent, thus suggesting the existence of differences between groups with and without diabetes [
44,
45]. The stents implanted in all patients of the present study were second-generation drug-eluting stents; as such, the effect of different types of implanted stents on cardiovascular events was minimised.
Table
5 shows the results of landmark analyses of the MACEs. FIB consistently revealed better predictive value for MACEs after PCI in the first 30 months than in the subsequent period (between the 31st month and end of follow-up). Significant interactions were found between time and FIB with respect to MACEs, which suggests that baseline FIB levels cannot accurately reflect patients’ fibrinolysis and coagulation status with prolonged follow-up. Additional studies addressing the effects of FIB level variability over time or the role of FIB isoform variability are required.
This study presents a number of advantages. First, we explored the relationship between FIB and glucose metabolism (HbA1c and FBG) in the whole, DM and non-DM populations with ACS. Results showed that baseline FIB is positively associated with HbA1c and FBG in the whole and DM populations with ACS, which helps enhance our understanding of the relationship between diabetes and FIB. Secondly, several reports on the relationship between FIB and cardiovascular events in patients with diabetes and/or CAD have been published [
38,
39]. Some studies focus on the association between FIB and long- or short-term MACEs in patients with ACS [
10,
11,
35]. However, few researchers have assessed 2-year MACEs in ACS populations after PCI with or without DM. Despite revascularisation, a large proportion of ACS patients continue to experience MACEs, which is worsened by DM. Thus, determining the relationship between FIB and MACEs in ACS patients with DM and without DM is meaningful. Finally, few scholars have explored the relationship between FIB and MACEs in a Chinese ACS population after PCI. In a study from Beijing, the association between FIB and cardiovascular events in patients with stable angina pectoris and T
2DM was assessed [
38]. However, the target population of this work is very different from that in the present study. Another study showed that FIB level at admission is independently associated with death risk amongst Chinese patients with ACS [
46]. However, this work did not explore the relationship between FIB and glucose metabolism or the relationship between FIB and 2-year MACEs in ACS patients after PCI with and without DM. Thus far, the present work is the first to study the relationship between FIB, glucose metabolism (HbA1c and FBG) and 2-year MACEs after PCI in ACS patents with and without DM in a prospective cohort from China.
This study features some limitations. Firstly, this study is a single-centre observational cohort study, which is less convincing than clinical trial studies. Secondly, only 411 ACS patients were enrolled in this work, amongst which only 103 patients had T2DM; this limitation may affect the reliability of the results. Finally, the study only included ACS patients undergoing PCI, which suggests that the study results may not be generalisable to all ACS patients.
Authors’ contributions
ZY conceived and designed the study; YW and LZ contributed to the design; LZ performed the study, JL, CX, RL, XB and LW help to the study; LZ analyzed the data and draft the paper; JZ contributed to the drafting. All authors read, critically revised the final manuscript. All authors read and approved the final manuscript.